Lantern Pharma Analyst Ratings
Lantern Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 135.55% | EF Hutton | → $11 | Reiterates | Buy → Buy |
| 06/26/2023 | 135.55% | EF Hutton | $11 → $11 | Maintains | Buy |
| 05/25/2023 | 135.55% | EF Hutton | → $11 | Assumes | → Buy |
| 05/18/2023 | — | HC Wainwright & Co. | Initiates Coverage On | → Neutral | |
| 03/21/2023 | 135.55% | EF Hutton | → $11 | Reiterates | → Buy |
| 02/15/2023 | 135.55% | EF Hutton | → $11 | Maintains | Buy |
| 11/01/2022 | 135.55% | EF Hutton | → $11 | Initiates Coverage On | → Buy |
| 03/11/2022 | 670.88% | HC Wainwright & Co. | $34 → $36 | Maintains | Buy |
| 11/02/2021 | 628.05% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/07/2021 | 585.22% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 07/28/2020 | 413.92% | Colliers Securities | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/10/2023 | 135.55% | EF Hutton | → 11 美元 | 重申 | 购买 → 购买 |
| 06/26/2023 | 135.55% | EF Hutton | 11 美元 → 11 美元 | 维护 | 购买 |
| 05/25/2023 | 135.55% | EF Hutton | → 11 美元 | 假设 | → 购买 |
| 05/18/2023 | — | HC Wainwright & Co. | 启动覆盖开启 | → 中立 | |
| 03/21/2023 | 135.55% | EF Hutton | → 11 美元 | 重申 | → 购买 |
| 02/15/2023 | 135.55% | EF Hutton | → 11 美元 | 维护 | 购买 |
| 11/01/2022 | 135.55% | EF Hutton | → 11 美元 | 启动覆盖开启 | → 购买 |
| 03/11/2022 | 670.88% | HC Wainwright & Co. | 34 美元 → 36 美元 | 维护 | 购买 |
| 11/02/2021 | 628.05% | HC Wainwright & Co. | 32 美元 → 34 美元 | 维护 | 购买 |
| 2021 年 7 月 10 日 | 585.22% | HC Wainwright & Co. | → 32 美元 | 启动覆盖开启 | → 购买 |
| 2020 年 7 月 28 日 | 413.92% | 高力证券 | → 24 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Lantern Pharma (LTRN)?
Lantern Pharma（LTRN）的目标价格是多少？
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on August 10, 2023. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 135.55% upside). 7 analyst firms have reported ratings in the last year.
EF Hutton于2023年8月10日公布了Lantern Pharma（纳斯达克股票代码：LTRN）的最新目标股价。这家分析公司将目标股价定为11.00美元，预计LTRN将在12个月内升至12个月内（可能上涨135.55％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Lantern Pharma (LTRN)?
分析师对Lantern Pharma（LTRN）的最新评级是多少？
The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma reiterated their buy rating.
Lantern Pharma（纳斯达克股票代码：LTRN）的最新分析师评级由EF Hutton提供，Lantern Pharma重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Lantern Pharma (LTRN)?
Lantern Pharma（LTRN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Lantern Pharma的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Lantern Pharma的最新评级是在2023年8月10日提交的，因此您应该预计下一个评级将在2024年8月10日左右公布。
Is the Analyst Rating Lantern Pharma (LTRN) correct?
分析师对Lantern Pharma（LTRN）的评级正确吗？
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a reiterated with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $4.67, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Lantern Pharma（LTRN）评级得到了重申，目标股价为0.00美元至11.00美元。Lantern Pharma（LTRN）目前的交易价格为4.67美元，在分析师的预测区间内。